289 related articles for article (PubMed ID: 31714764)
1. Synthesis, Characterization, and Biological Properties of Steroidal Ruthenium(II) and Iridium(III) Complexes Based on the Androst-16-en-3-ol Framework.
Koch V; Meschkov A; Feuerstein W; Pfeifer J; Fuhr O; Nieger M; Schepers U; Bräse S
Inorg Chem; 2019 Dec; 58(23):15917-15926. PubMed ID: 31714764
[TBL] [Abstract][Full Text] [Related]
2. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
3. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
4. Hetero-Bis-Conjugation of Bioactive Molecules to Half-Sandwich Ruthenium(II) and Iridium(III) Complexes Provides Synergic Effects in Cancer Cell Cytotoxicity.
Biancalana L; Kostrhunova H; Batchelor LK; Hadiji M; Degano I; Pampaloni G; Zacchini S; Dyson PJ; Brabec V; Marchetti F
Inorg Chem; 2021 Jul; 60(13):9529-9541. PubMed ID: 34156246
[TBL] [Abstract][Full Text] [Related]
5. Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes.
Ludwig G; Mojić M; Bulatović M; Mijatović S; Maksimović-Ivanić D; Steinborn D; Kaluđerović GN
Anticancer Agents Med Chem; 2016; 16(11):1455-1460. PubMed ID: 26510901
[TBL] [Abstract][Full Text] [Related]
6. Rhodamine-modified fluorescent half-sandwich iridium and ruthenium complexes: potential application as bioimaging and anticancer agents.
Ma W; Guo L; Tian Z; Zhang S; He X; Li J; Yang Y; Liu Z
Dalton Trans; 2019 Apr; 48(15):4788-4793. PubMed ID: 30892340
[TBL] [Abstract][Full Text] [Related]
7. Antitumor Effects of Ir(III)-2
Panchangam RL; Rao RN; Balamurali MM; Hingamire TB; Shanmugam D; Manickam V; Chanda K
Inorg Chem; 2021 Dec; 60(23):17593-17607. PubMed ID: 34767343
[TBL] [Abstract][Full Text] [Related]
8. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
[TBL] [Abstract][Full Text] [Related]
9. Similarities and differences in d
Gilewska A; Barszcz B; Masternak J; Kazimierczuk K; Sitkowski J; Wietrzyk J; Turlej E
J Biol Inorg Chem; 2019 Jun; 24(4):591-606. PubMed ID: 31115765
[TBL] [Abstract][Full Text] [Related]
10. Serendipitous Synthesis of Five-Coordinated Half-Sandwich Aminoimine Iridium(III) and Ruthenium(II) Complexes and Their Application as Potent Anticancer Agents.
Du Q; Guo L; Ge X; Zhao L; Tian Z; Liu X; Zhang F; Liu Z
Inorg Chem; 2019 May; 58(9):5956-5965. PubMed ID: 30986046
[TBL] [Abstract][Full Text] [Related]
11. A mitochondria-targeting dinuclear Ir-Ru complex as a synergistic photoactivated chemotherapy and photodynamic therapy agent against cisplatin-resistant tumour cells.
Zhang C; Guan R; Liao X; Ouyang C; Rees TW; Liu J; Chen Y; Ji L; Chao H
Chem Commun (Camb); 2019 Oct; 55(83):12547-12550. PubMed ID: 31576841
[TBL] [Abstract][Full Text] [Related]
12. Mitochondria-targeted phosphorescent cyclometalated iridium(III) complexes: synthesis, characterization, and anticancer properties.
Li Y; Liu B; Xu CX; He L; Wan YC; Ji LN; Mao ZW
J Biol Inorg Chem; 2020 Jun; 25(4):597-607. PubMed ID: 32232583
[TBL] [Abstract][Full Text] [Related]
13. On the antitumor properties of novel cyclometalated benzimidazole Ru(II), Ir(III) and Rh(III) complexes.
Yellol GS; Donaire A; Yellol JG; Vasylyeva V; Janiak C; Ruiz J
Chem Commun (Camb); 2013 Dec; 49(98):11533-5. PubMed ID: 24177492
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization and anticancer mechanism studies of fluorinated cyclometalated ruthenium(ii) complexes.
Wen Y; Ouyang C; Li Q; Rees TW; Qiu K; Ji L; Chao H
Dalton Trans; 2020 Jun; 49(21):7044-7052. PubMed ID: 32406463
[TBL] [Abstract][Full Text] [Related]
15. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Antitumor Activity Evaluation of Cyclometalated 2H-Indazole Ruthenium(II) and Iridium(III) Complexes.
Rao RN; Panchangam RL; Manickam V; Balamurali MM; Chanda K
Chempluschem; 2020 Aug; 85(8):1800-1812. PubMed ID: 32820621
[TBL] [Abstract][Full Text] [Related]
17. Alkyl chain-modified cyclometalated iridium complexes as tunable anticancer and imaging agents.
Laha P; De U; Chandra F; Dehury N; Khullar S; Kim HS; Patra S
Dalton Trans; 2018 Nov; 47(44):15873-15881. PubMed ID: 30358775
[TBL] [Abstract][Full Text] [Related]
18. Half-sandwich ruthenium(ii) complexes containing N^N-chelated imino-pyridyl ligands that are selectively toxic to cancer cells.
Tian M; Li J; Zhang S; Guo L; He X; Kong D; Zhang H; Liu Z
Chem Commun (Camb); 2017 Nov; 53(95):12810-12813. PubMed ID: 29143019
[TBL] [Abstract][Full Text] [Related]
19. Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(ii) carbazole-based hydrazone complexes.
Sathiya Kamatchi T; Mohamed Subarkhan MK; Ramesh R; Wang H; Małecki JG
Dalton Trans; 2020 Aug; 49(32):11385-11395. PubMed ID: 32776042
[TBL] [Abstract][Full Text] [Related]
20. Reactive Oxygen Species Production Is Responsible for Antineoplastic Activity of Osmium, Ruthenium, Iridium and Rhodium Half-Sandwich Type Complexes with Bidentate Glycosyl Heterocyclic Ligands in Various Cancer Cell Models.
Kacsir I; Sipos A; Bényei A; Janka E; Buglyó P; Somsák L; Bai P; Bokor É
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
